Profile data is unavailable for this security.
About the company
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.
- Revenue in USD (TTM)0.00
- Net income in USD-73.10m
- Incorporated2014
- Employees54.00
- LocationBlack Diamond Therapeutics IncOne Main Street, 14Th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 417-5868
- Fax+1 (302) 655-5049
- Websitehttps://www.blackdiamondtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | 689.00k | -43.01m | 176.92m | 31.00 | -- | 3.41 | -- | 256.78 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 178.26m | 75.00 | -- | 2.61 | -- | 28.82 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Galectin Therapeutics Inc | 0.00 | -48.03m | 179.98m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.90m | 180.82m | 18.00 | -- | 3.38 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.22m | 184.81m | 3.00 | -- | 31.27 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Aclaris Therapeutics Inc | 27.08m | -37.00m | 187.86m | 91.00 | -- | 1.44 | -- | 6.94 | -0.5198 | -0.5198 | 0.3806 | 1.82 | 0.1352 | -- | 78.61 | 297,582.40 | -18.47 | -47.29 | -20.87 | -53.87 | 53.53 | 44.00 | -136.65 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Sagimet Biosciences Inc | 2.00m | -29.25m | 188.34m | 10.00 | -- | 1.02 | -- | 94.17 | -1.18 | -1.18 | 0.078 | 5.74 | 0.019 | -- | -- | 200,000.00 | -27.79 | -- | -29.32 | -- | -- | -- | -1,462.55 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 79.57k | -18.38m | 188.77m | 8.00 | -- | 4.06 | -- | 2,372.40 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -73.10m | 191.26m | 54.00 | -- | 1.96 | -- | -- | -1.36 | -1.36 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -47.12 | -40.29 | -53.28 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 193.46m | 51.00 | -- | 0.793 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
| Gossamer Bio Inc | 105.32m | -71.65m | 194.15m | 135.00 | -- | 3.59 | -- | 1.84 | -0.3283 | -0.3283 | 0.4595 | 0.2389 | 0.3014 | -- | -- | 780,162.90 | -20.51 | -57.43 | -23.67 | -64.38 | -- | -- | -68.03 | -- | -- | -6.84 | 0.7847 | -- | -- | -- | 21.61 | -- | -- | -- |
| Verastem Inc | 10.00m | -93.45m | 198.50m | 73.00 | -- | 16.24 | -- | 19.85 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 203.60m | 140.00 | -- | 1.81 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -25.91m | 203.73m | 10.00 | -- | 2.54 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| CAMP4 Therapeutics Corp | 350.00k | -49.71m | 205.00m | 58.00 | -- | -- | -- | 585.71 | -2.55 | -2.55 | 0.0179 | 0.7707 | -- | -- | -- | 5,468.75 | -- | -- | -- | -- | -- | -- | -14,203.71 | -- | -- | -- | 0.0221 | -- | -- | -- | -11.54 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Black Diamond Therapeutics Inc's reporting currency: US Dollar USD
54.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 10.66m | 18.87% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 8.52m | 15.08% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.14m | 3.78% |
| Vestal Point Capital LPas of 30 Jun 2024 | 2.10m | 3.72% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.07m | 3.66% |
| Tang Capital Management LLCas of 30 Jun 2024 | 1.60m | 2.84% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 1.05m | 1.85% |
| Millennium Management LLCas of 30 Jun 2024 | 1.00m | 1.78% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 916.13k | 1.62% |
| Geode Capital Management LLCas of 30 Jun 2024 | 842.43k | 1.49% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
